1. Home
  2. NVNI vs IVVD Comparison

NVNI vs IVVD Comparison

Compare NVNI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

HOLD

Current Price

$4.05

Market Cap

57.2M

Sector

N/A

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$2.23

Market Cap

692.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVNI
IVVD
Founded
2019
2020
Country
Brazil
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.2M
692.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NVNI
IVVD
Price
$4.05
$2.23
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.33
AVG Volume (30 Days)
150.9K
12.0M
Earning Date
09-30-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,250,627.00
$50,039,000.00
Revenue This Year
$12.05
$103.88
Revenue Next Year
$15.02
$171.40
P/E Ratio
N/A
N/A
Revenue Growth
1491.58
332.71
52 Week Low
$1.44
$0.35
52 Week High
$121.90
$3.07

Technical Indicators

Market Signals
Indicator
NVNI
IVVD
Relative Strength Index (RSI) 69.09 53.98
Support Level $2.80 $2.09
Resistance Level $3.00 $2.60
Average True Range (ATR) 0.27 0.22
MACD 0.07 -0.04
Stochastic Oscillator 89.73 17.86

Price Performance

Historical Comparison
NVNI
IVVD

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: